RESEARCH ARTICLE

Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores

Renling Yao1,2 | Li Zhu3 | Jian Wang2 | Jiacheng Liu4 | Ruifei Xue1 | Leyang Xue5 | Longgen Liu6 | Chunyang Li7 | Haiyan Zhao8 | Juan Cheng9 | Songping Huang10 | Yang Li11 | Xiang-an Zhao12 | Chuanwu Zhu3 | Ming Li13 | Rui Huang2 | Chao Wu1,2,4

1Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China
2Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
3Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
4Department of Critical Medicine, Hua'an No. 4 People's Hospital, Hua'an, China
5Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China
6Department of Infectious Diseases, The Third People's Hospital of Changzhou, Changzhou, China
7Department of Infectious Diseases, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
8Department of Infectious Diseases, The People's Hospital of Suqian, Suqian, China
9Department of Infectious Diseases, Yancheng Second People's Hospital, Yancheng, China
10Department of Infectious Diseases, Nantong Third People's Hospital, Nantong University, Nantong, China
11Department of Infectious Diseases, Taizhou People's Hospital, Taizhou, China
12Department of Gastroenterology, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, China
13Department of Hepatology, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, China

Abstract

Background: There is still little knowledge about the association of liver fibrosis with the clinical outcomes of COVID-19 patients with non-alcoholic fatty liver disease (NAFLD). The aim of the study was to determine the association of NAFLD fibrosis score (NFS)–determined liver fibrosis with clinical outcomes of COVID-19 patients with NAFLD.

Methods: The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of chronic liver diseases. NFS was used to evaluate the severity of liver fibrosis.

Results: A total of 86 COVID-19 patients with NAFLD were included. The median age was 43.5 years, and 58.1% of patients were male. Thirty-eight (44.2%) patients had advanced liver fibrosis according to the NFS. Multivariate analysis indicated that concurrent diabetes (odds ratio [OR] 8.264, 95% confidence interval [CI] 1.202–56.830, \( p = 0.032 \)) and advanced liver fibrosis (OR 11.057, 95% CI 1.193–102.439, \( p = 0.034 \)) were independent risk factors of severe illness in COVID-19 patients with NAFLD.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
1 | INTRODUCTION

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected millions of individuals globally. The spectrum of COVID-19 ranges from asymptomatic disease to critical illness with fatal outcome.\(^1\) Given the significant impacts of disease severity on prognosis of COVID, much interest has been paid to identify the risk factors associated with severe illness of COVID-19. Several factors, such as older age, pre-existing lung disease, diabetes mellitus, cardiovascular disease, and obesity, are associated with the severe illness of COVID-19.\(^1\) Chronic liver disease (CLD) is another comorbid condition that is being evaluated for its impact on COVID-19 severity. It is reported that 2%-11% of patients with COVID-19 had comorbidities of CLDs.\(^6\) Non-alcoholic fatty liver disease (NAFLD) is one of the most common CLDs worldwide.\(^7\) The global prevalence of NAFLD in general population is 6.3%-45%.\(^7,8\) In most Asian countries including China, the prevalence of NAFLD is above 25%.\(^9\)

Our previous study demonstrated that 30.7% of COVID-19 patients had NAFLD.\(^10\) We also found that COVID-19 patients with NAFLD are more likely to develop liver injury.\(^10\) Ji et al. found that COVID-19 patients with fatty liver had a higher risk of disease progression, higher likelihood of abnormal liver function tests, and longer shedding time of SARS-CoV-2 virus.\(^11\) Mushtaq et al also reported that NAFLD was an independent predictor of liver injury in hospitalized patients with COVID-19, while NAFLD was not identified as an independent predictor of mortality, disease severity, or disease progression.\(^12\) NAFLD includes a wide spectrum of CLDs, from steatosis to non-alcoholic steatohepatitis, with a variable stage of fibrosis to cirrhosis.\(^13\) The association of severity of liver fibrosis and the COVID-19 is not yet clear. Targher et al. found that metabolic dysfunction-associated fatty liver disease (MAFLD) patients with increased FIB-4 are at a higher risk of severe illness of COVID-19.\(^14\) The NAFLD fibrosis score (NFS) was demonstrated to identify NAFLD patients with and without advanced fibrosis independently.\(^15\) Nevertheless, at present, there is still little knowledge about the association of NFS with the severity of COVID-19 patients with NAFLD. We aimed to determine the association of NFS-determined liver fibrosis with clinical outcomes of COVID-19 in NAFLD patients.

2 | METHODS

2.1 | Study design and data collection

We retrospectively screened 342 consecutively confirmed COVID-19 patients who were admitted to hospitals between January 18, 2020, and February 26, 2020, from ten designated hospitals of Jiangsu Province, China. The patients were followed up to February 29, 2020. The COVID-19 was diagnosed according to the guidance provided by the World Health Organization (WHO).\(^16\)

Patients with viral hepatitis defined by positive serum hepatitis B surface antigen and/or hepatitis C antibody and/or a known history of chronic hepatitis B or chronic hepatitis C were excluded. Patients with a known history of autoimmune liver diseases, or any other chronic liver diseases were also excluded. In addition, we excluded patients with significant alcohol consumption defined by >30 g/day in men and >20 g/day in women. The epidemiological, clinical data and outcomes were collected from medical records of patients.

The study was approved by the Ethics Committees of these hospitals, with a waiver of informed consent.

2.2 | Definition of NAFLD, fibrosis, and severe illness

The NAFLD was diagnosed by the Hepatic Steatosis Index (HSI) in the absence of other causes of CLDs.\(^17\) The HSI was calculated by the equation: HSI = 8 × (ALT/AST ratio) + BMI (+2, if female; +2, if diabetes).\(^17\) Serum ALT and AST levels of the first test after patient admission were used for the calculation of the HSI. A cutoff of 36 of HSI was used to diagnose the presence of NAFLD.\(^18-20\) The HSI has been validated and used in previous studies.\(^18-20\)

NAFLD fibrosis score was used to evaluate the severity of liver fibrosis.\(^15\) NFS was calculated by the following formula: NFS = \(-1.675 + 0.037 \times \text{age (year)} + 0.094 \times \text{BMI (kg/m}^2\) + 1.13 \times \text{IFG/diabetes (yes = 1, no = 0)} + 0.99 \times \text{AST/ALT ratio} - 0.013 \times \text{platelet count (×10}^9\text{/L)} - 0.66 \times \text{albumin (g/dL)}\).\(^15\) Patients were separated into two groups: advanced liver fibrosis (ALF) and non-advanced liver fibrosis (non-ALF) according to NFS.\(^15,21\) Patients with NFS < -1.5 were defined as non-ALF, while patients with the NFS at least -1.5 were defined as ALF.\(^15\)

---

**Conclusion:** NAFLD patients with NFS-determined advanced liver fibrosis are at higher risk of severe COVID-19.

**KEYWORDS**

COVID-19, fibrosis, non-alcoholic fatty liver disease, severe illness
Severe illness of COVID-19 was defined as COVID-19 patients who fulfilled any of the following criteria: (1) respiratory frequency ≥ 30/min, (2) pulse oximeter oxygen saturation ≤ 93% at rest, and (3) oxygenation index ≤ 300 mmHg.\textsuperscript{22}

2.3 Statistical analysis

Data were analyzed by SPSS version 22.0 software (SPSS Inc., Chicago, IL, United States). Continuous data were shown as medians and interquartile range (IQR), while categorical data were presented as the counts and percentages. Two-sample t tests or Mann-Whitney U test were used to compare the continuous variables between two groups as appropriate, while chi-square tests or Fisher’s exact tests were used to compare the categorical variables. Logistic regression analysis was used to identify the risk factors of ALF. Variables having \( p \) values < 0.1 in the univariate analysis were used for a multivariate input logistic regression analysis. Age and gender were also adjusted by the multivariate logistic regression analysis. \( p \) < 0.05 was considered statistically significant.

3 RESULTS

3.1 Demographic characteristics and onset symptoms

Among 342 screened patients with COVID-19, 34 patients lacking BMI data, 7 patients with insufficient biochemistry data, 7 patients with alcohol abuse, and 14 patients concomitant with other chronic liver diseases (12 chronic hepatitis B, 1 chronic hepatitis C, and 1 Dubin-Johnson syndrome) were excluded. 194 COVID-19 patients without NAFLD identified by HSI were also excluded. Finally, 86 COVID-19 patients with NAFLD were included in this study. Among the 86 patients consisting of 38 patients with ALF, the median age was 43.5 (IQR, 32.8–53.3) years and 58.1% were male. Patients with ALF were older (median 52.0 vs. 36.5 years, \( p \) < 0.001). More NAFLD patients with ALF had obese (63.2% vs. 22.9%, \( p \) < 0.001) and diabetes (23.7% vs. 2.1%, \( p \) = 0.006). More NAFLD patients with ALF had fever (81.6% vs. 50.0%, \( p \) = 0.002) and shortness of breath (18.4% vs. 0, \( p \) = 0.007). Moreover, the proportion of patients with severe illness was also significantly higher in the ALF compared to patients with non-ALF (28.9% vs. 2.1%, \( p \) < 0.001) (Table 1).

3.2 Laboratory and radiology examination

The baseline lymphocyte counts, platelet counts, and albumin levels were significantly lower in NAFLD patients with ALF compared with patients with non-ALF (all \( p \) < 0.001). All NAFLD patients with ALF had pneumonia in chest CT and most (92.1%) of the patients had bilateral pneumonia. However, 12.5% of the NALFD patients with non-ALF presented no pneumonia in chest CT. The proportion of pneumonia was higher in NAFLD patients with ALF than patients with non-ALF (\( p \) = 0.028) (Table 2).

3.3 Risk factors of severe illness during hospitalization

Logistic regression analysis was performed to identify the risk factors of severe illness in COVID-19 patients. The univariate analysis revealed that obese (BMI \( \geq 28 \text{ kg/m}^2 \)) (odds ratio [OR] 5.538, 95% confidence interval [CI] 1.378–22.260, \( p \) = 0.016), concurrent diabetes (OR 9.857, 95% CI 2.282–42.582, \( p \) = 0.002), and ALF (OR 19.148, 95% CI 2.342–156.542, \( p \) = 0.006) were associated with severe illness. Multivariate analysis indicated that concurrent diabetes (OR 8.264, 95% CI 1.202–56.830, \( p \) = 0.032) and ALF (OR 11.057, 95% CI 1.193–102.439, \( p \) = 0.034) were independent risk factors of severe illness in COVID-19 patients with NAFLD (Table 3).

4 DISCUSSION

The presence of NAFLD has been reported as a predictor of the development of liver injury.\textsuperscript{11,12} In our previous study, we also demonstrated that COVID-19 patients with NAFLD are more likely to develop liver injury.\textsuperscript{10} However, the association of liver fibrosis and the severity of COVID-19 is not yet clear. Forlano et al reported that the presence of intermediate/high-risk FIB-4 or liver cirrhosis was not associated with ICU admission and in-hospital mortality of NAFLD patients with COVID-19.\textsuperscript{23} However, the sample size is very small which only included 38 patients.\textsuperscript{23} Targar et al reported that the severity of COVID-19 was associated with intermediate (unadjusted OR 4.32) or high (unadjusted OR 5.73) FIB-4 scores in patients with MAFLD.\textsuperscript{14} The non-invasive fibrosis scores such as FIB-4 and NFS have been shown to predict fibrosis stage of NAFLD patients with reasonable accuracy.\textsuperscript{24,25} NFS score was initially developed to evaluate liver fibrosis degree in NAFLD patients.\textsuperscript{15} A prospective study demonstrated that NFS had a more excellent discriminatory ability for the detection of advanced fibrosis than FIB-4.\textsuperscript{26} Another study also reported that NFS had the highest discriminatory accuracy for advanced fibrosis compared with FIB-4.\textsuperscript{27} However, there was no study investigating the association with NFS and the severity of COVID-19 in patients with NAFLD. In this study, we found that 44.2% of the NAFLD patients with COVID-19 had ALF according the NFS. Furthermore, we found that COVID-19 patients with NAFLD and increased NFS was an independent risk factor of severe illness of patients with COVID-19. We also found that the presence of diabetes was an independent risk factor of severe illness of COVID-19 which is consistent with the previous study.\textsuperscript{28}
The exact pathophysiology on how ALF contributes to a more severe COVID-19 illness in NAFLD patients is not yet clear, while several potential mechanisms have been proposed. Systemic inflammatory response syndrome, especially the “cytokine storm,” is one of the important pathophysiologic mechanisms for the development of severe illness in COVID-19.29 The presence of ALF might exacerbate the virus-induced "cytokine storm" and thereby contribute to severe COVID-19 through the hepatic release of proinflammatory cytokines.14 However, more studies are needed to explore the mechanisms of advanced NAFLD contributing to the COVID-19 disease process.

Our study has some limitations. First, the sample size of our study is relatively small. Second, we use the non-invasive fibrosis scores to diagnose fibrosis without a histological diagnosis of liver fibrosis. Other non-invasive tests such as transient elastography by FibroScan may be more reliable for the liver fibrosis and steatosis assessment.30 However, during the early stages of the COVID-19 outbreak, the transient elastography was not performed in the patients. Third, we did not analyze the risk factors of ICU admission of COVID-19 patients with NAFLD since only 5 patients were admitted to the ICU. Fourth, given that the quality of care may vary across hospitals, the results might be biased by the heterogeneity of care across hospitals. However, all patients were treated according to the guidelines for the Diagnosis and Treatment of coronavirus disease 2019 (COVID-19) issued by the National Health Commission of China.22 Thus, we consider the quality of care across hospitals might not significantly impact our results.

Our study demonstrates that patients with NAFLD with NFS-determined ALF are at higher risk of having severe COVID-19. However, more studies with large sample size are needed to validate

| Variables (n [%] or median [IQR]) | Non-ALF (n = 48) | ALF (n = 38) | p value |
|-----------------------------------|-----------------|-------------|---------|
| Age (years)                       | 36.5 (29.0,47.0) | 52.0 (43.3,63.0) | <0.001  |
| Age range                         |                 |             |         |
| ≤60                               | 46 (95.8)       | 28 (73.7)   | 0.003   |
| >60                               | 2 (4.2)         | 10 (26.3)   |         |
| Gender                            |                 |             |         |
| Male                              | 29 (60.4)       | 21 (55.3)   | 0.630   |
| Female                            | 19 (39.6)       | 17 (44.7)   |         |
| BMI (kg/m²)                       | 25.8 (24.5,27.7) | 28.9 (26.8,30.2) | <0.001 |
| BMI range                         |                 |             |         |
| <28                               | 37 (77.1)       | 14 (36.8)   | <0.001  |
| ≥28                               | 11 (22.9)       | 24 (63.2)   |         |
| Onset signs and symptoms          |                 |             |         |
| Fever                             | 24 (50.0)       | 31 (81.6)   | 0.002   |
| Cough                             | 25 (52.1)       | 22 (57.9)   | 0.591   |
| Fatigue                           | 8 (16.7)        | 8 (21.1)    | 0.604   |
| Sore throat                       | 6 (12.5)        | 4 (10.5)    | 1.000   |
| Muscle ache                       | 4 (8.3)         | 3 (7.9)     | 1.000   |
| Shortness of breath               | 0               | 7 (18.4)    | 0.007   |
| Headache                          | 2 (4.2)         | 1 (2.6)     | 1.000   |
| Comorbidities                     |                 |             |         |
| Any comorbidity                   | 9 (18.8)        | 18 (47.4)   | 0.005   |
| Hypertension                      | 6 (12.5)        | 12 (31.6)   | 0.031   |
| Diabetes                          | 1 (2.1)         | 9 (23.7)    | 0.006   |
| Chronic lung diseases             | 2 (4.2)         | 0           | 0.124   |
| Outcomes                          |                 |             |         |
| Severe illness                    | 1 (2.1)         | 11 (28.9)   | <0.001  |
| Admission to ICU                  | 1 (2.1)         | 4 (10.5)    | 0.231   |
| Death                             | 0               | 0           |         |

Abbreviations: ALF, advanced liver fibrosis; BMI, body mass index; ICU, intensive care unit; IQR, interquartile range.

*Any comorbidity denoted for patients accompanied with one or more chronic diseases, such as hypertension, diabetes, and chronic lung diseases.
### TABLE 2 Baseline laboratory parameters and chest CT of COVID-19 patients who have NAFLD with or without advanced liver fibrosis

| Variables | Non-ALF (n = 48) | ALF (n = 38) | p value |
|-----------|-----------------|--------------|---------|
| WBC (×10⁹/L) | 6.1 (4.9, 6.9) | 5.1 (3.9, 6.7) | 0.086 |
| Lymphocytes (×10⁹/L) | 1.6 (1.2, 2.2) | 1.1 (0.8, 1.6) | <0.001 |
| PLT (×10⁹/L) | 227.5 (197.0, 276.0) | 152.0 (124.0, 178.5) | <0.001 |
| ALT (U/L) | 36.5 (25.3, 48.5) | 33.5 (24.8, 55.3) | 0.955 |
| AST (U/L) | 23.4 (19.0, 27.8) | 31.0 (23.8, 43.5) | <0.001 |
| GGT (U/L) | 32.5 (16.2, 48.0) | 36.5 (27.8, 52.9) | 0.095 |
| Tbil (μmol/L) | 11.3 (7.9, 16.2) | 10.7 (7.7, 17.5) | 0.920 |
| ALB (g/L) | 42.8 (39.1, 46.7) | 37.4 (31.4, 44.5) | <0.001 |
| ALP (U/L) | 65.0 (51.0, 73.0) | 62.0 (51.5, 72.8) | 0.733 |
| FBG (mmol/L) | 5.2 (4.8, 5.9) | 6.5 (5.5, 8.0) | <0.001 |
| TG (mmol/L) | 1.4 (1.0, 2.3) | 1.4 (1.0, 1.5) | 0.404 |
| TC (moll/L) | 3.9 (3.3, 4.6) | 4.0 (3.4, 4.7) | 0.641 |

Chest CT
- No pneumonia | 6 (12.5) | 0 | 0.028 |
- Unilateral pneumonia | 8 (16.7) | 3 (7.9) |
- Bilateral pneumonia | 34 (70.8) | 35 (92.1) |

Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; NAFLD, non-alcoholic fatty liver disease; PLT, platelet; Tbil, total bilirubin.

### TABLE 3 Risk factors of severe illness during hospitalization in COVID-19 patients

| Variables | Univariate | Multivariate |
|-----------|------------|--------------|
|           | OR (95%CI) | p value      | OR (95%CI) | p value      |
| Age (years) |            |              |            |              |
| ≤60       | Reference  |              |            |              |
| >60       | 1.280 (0.244, 6.719) | 0.770 | 4.891 (0.538, 44.451) | 0.159 |
| Gender    |            |              |            |              |
| Female    | Reference  |              |            |              |
| Male      | 1.009 (0.293, 3.478) | 0.988 | 0.698 (0.150, 3.239) | 0.646 |
| BMI (kg/m²) |            |              |            |              |
| <28       | Reference  |              |            |              |
| ≥28       | 5.538 (1.378, 22.260) | 0.016 | 3.320 (0.644, 17.103) | 3.320 |
| Hypertension |            |              |            |              |
| No        | Reference  |              |            |              |
| Yes       | 0.305 (0.037, 2.533) | 0.271 |              |              |
| Diabetes  |            |              |            |              |
| No        | Reference  |              |            |              |
| Yes       | 9.857 (2.282, 42.582) | 0.002 | 8.264 (1.202, 56.830) | 0.032 |
| Advanced liver fibrosis |            |              |            |              |
| No        | Reference  |              |            |              |
| Yes       | 19.148 (2.342, 156.542) | 0.006 | 11.057 (1.193, 102.439) | 0.034 |

Abbreviations: BMI, body mass index; CI, confidence interval; ICU, intensive care unit; OR, odd ratio.
our results and to better understand the mechanistic link of advanced NAFLD and severe COVID-19.

CONFLICTS OF INTEREST
The authors have declared that no conflicts of interest exist.

AUTHORS' CONTRIBUTIONS
Concept and design: Chao Wu, Rui Huang and Ming Li. Drafting of the manuscript: Renling Yao, Rui Huang, Jian Wang, Li Zhu, Jiacheng Liu; Critical revision of the manuscript for important intellectual content: Chuanwu Zhu and Ming Li; Statistical analysis: Jian Wang and Jiacheng Liu; Administrative, technical, or material support: Longgen Liu, Haiyan Zhao; Supervision: Ming Li, Chao Wu and Rui Huang; Acquisition, analysis, or interpretation of data: Renling Yao, Rui Huang, Jian Wang, Jiacheng Liu, Ruifei Xue, Leyang Xue, Songping Huang, Xiang-an Zhao, Chunyang Li, Yang Li and Juan Cheng.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Jian Wang https://orcid.org/0000-0001-5004-0877
Chao Wu https://orcid.org/0000-0002-1657-010X

REFERENCES
1. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.
2. Huang R, Zhu L, Xue L, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Negl Trop Dis. 2020;14:e0008280.
3. Wang J, Zhu L, Liu L, et al. Overweight and obesity are risk factors of severe illness in patients with COVID-19. Obesity. 2020;28:2049-2055.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
5. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-436.
6. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428-430.
7. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
8. Fan JG, Wei L, Zhuang H, et al. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis. 2019;20:163-173.
9. Wu Y, Zheng QI, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14:259-269.
10. Huang R, Zhu L, Wang J, et al. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol Commun. 2020;4:1758-1768.
11. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73:451-453.
12. Mushfaq K, Khan MU, Iqbal F, et al. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - the debate continues. J Hepatol. 2021;74:482-484.
13. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402.
14. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1543-1547.
15. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854.
16. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. Published January 28, 2020. https://apps.who.int/iris/bitstream/handle/10665/330854/WHO-nCoV-Clinical-2020-2-eng.pdf?sequence=1&isAllowed=y. Accessed January 31, 2020.
17. Lee J-H, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503-508.
18. Kim D, Yoo ER, Li AA, et al. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther. 2019;50:590-598.
19. Kim D, Kim W, Adejumo AC, et al. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. Hepatol Int. 2019;13:205-213.
20. Kim D, Yoo ER, Li AA, et al. Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States. Liver Int. 2019;39:1335-1342.
21. Treeprasertsuk S, Björnsson E, Enders F, et al. NAFLD fibrosis score: a diagnostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19:1219-1229.
22. National Health Commission. Guidelines for the Diagnosis and Treatment of coronavirus disease 2019 (COVID-19) by the National Health Commission (Trial Version 7). http://www.NhcGovCn/Xcs/Clinical-2020.2-eng.pdf?sequence=1&isAllowed=y. Accessed Mar 3, 2021.
23. Forlano R, Mullish BH, Mukherjee SK, et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400.
24. Villar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315.
25. Durazzo M, Marzari L, Bonetto S, et al. Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. Minerva Gastroenterol Dietol. 2020;66:301-306.
26. Causse Y, Ajmery VH, Puri P, et al. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut. 2019;68:1884-1892.
27. Balakrishnan M, Seth A, Cortes-Santiago N, et al. External validation of four point-of-care noninvasive scores for predicting advanced hepatic fibrosis in a predominantly hispanic NAFLD population. Dig Dis Sci. 2020. [Epub ahead of print].
28. Targher G, Mantovani A, Wang X-B, et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. 2020;46:335-337.

29. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

30. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264.

How to cite this article: Yao R, Zhu L, Wang J, et al. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores. J Clin Lab Anal. 2021;35:e23880. https://doi.org/10.1002/jcla.23880